Category 5 - DIAGNOSTIC IMAGING SERVICES
61528 - Additional Information
Item Start Date:
01-Jul-2025
Description Updated:
01-Jul-2025
Schedule Fee Updated:
01-Jul-2025
Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET
Whole body PSMA PET study, performed for the assessment of suitability for Lutetium 177 PSMA therapy in a patient with metastatic castrate resistant prostate cancer, after progressive disease has developed while undergoing prior treatment with at least one taxane chemotherapy and at least one androgen receptor signalling inhibitor.
(R)
(Anaes.)
Fee: $1,300.00 Benefit: 75% = $975.00 85% = $1,195.50
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change